Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide and Atorvastatin for Chronic Mountain Sickness
NCT04251364Completed
- Sponsor
- EXALT
- Start
- Feb 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Chronic Mountain Sickness (CMS) comparing Acetazolamide, Atorvastatin and Placebo (3 arms). Primary endpoint: Change in hematocrit at 9 months. Started Feb 2020; status: completed.
02
Drugs
acetazolamideatorvastatin
03
Conditions
Chronic Mountain Sickness (CMS)
Beyond the preview
Go deeper on NCT04251364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251364.